Albers Jeffrey W. 4
4 · Kymera Therapeutics, Inc. · Filed Jun 3, 2025
Insider Transaction Report
Form 4
Albers Jeffrey W.
Director
Transactions
- Sale
Common Stock
2025-06-03$49.00/sh−6,349$311,101→ 0 total - Exercise/Conversion
Common Stock
2025-06-03$10.34/sh+6,349$65,649→ 6,349 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-06-03−6,349→ 5,000 totalExercise: $10.34Exp: 2030-09-03→ Common Stock (6,349 underlying)
Footnotes (2)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 20, 2024 adopted by the reporting person.
- [F2]The shares underlying this stock option are fully vested and exercisable.